News
Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback